Top

Published in:

Open Access 01-03-2020 | Literatur kommentiert

Ribociclib in Kombination mit endokriner Therapie verbessert Überleben von prä-/perimenopausalen Mammakarzinom-Patientinnen

Authors: Dr. med. David Krug, Alexander Fabian, Jürgen Dunst

Published in: Strahlentherapie und Onkologie | Issue 3/2020

Auszug

Die zugelassenen Inhibitoren der Cyclin-abhängigen Kinasen 4/6 (CDK4/6i) Palbociclib, Ribociclib und Abemaciclib verbessern das progressionsfreie Überleben von Patientinnen mit Hormonrezeptor-positivem (HR-pos.), HER2-negativem (HER2-neg.) Mammakarzinom in Kombination mit einer endokrinen Therapie deutlich. Die vorgestellte Arbeit präsentiert Daten zum Gesamtüberleben („overall survival“, OS) aus der MONALEESA-7-Studie. …

Thill M, Jackisch C, Janni W et al (2019) AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2019. Breast Care 14:1–9. https://doi.org/10.1159/000500999CrossRef

Cristofanilli M, Turner NC, Bondarenko I et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439. https://doi.org/10.1016/S1470-2045(15)00613-0CrossRefPubMed

André F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med 380:1929–1940. https://doi.org/10.1056/NEJMoa1813904CrossRefPubMed

Robson M, Im S‑A, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med 377:523–533. https://doi.org/10.1056/NEJMoa1706450CrossRefPubMed

Mehta RS, Barlow WE, Albain KS et al (2019) Overall survival with Fulvestrant plus Anastrozole in metastatic breast cancer. N Engl J Med 380:1226–1234. https://doi.org/10.1056/NEJMoa1811714CrossRefPubMedPubMedCentral

Chowdhary M, Sen N, Chowdhary A et al (2019) Safety and efficacy of Palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination. Adv Radiat Oncol 4:453–457. https://doi.org/10.1016/j.adro.2019.03.011CrossRefPubMedPubMedCentral

Figura NB, Potluri TK, Mohammadi H et al (2019) CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. https://doi.org/10.1007/s11060-019-03260-6CrossRefPubMed

Hans S, Cottu P, Kirova YM (2018) Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients. Radiother Oncol 126:181. https://doi.org/10.1016/j.radonc.2017.09.010CrossRefPubMed

Meattini I, Desideri I, Scotti V et al (2018) Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. Breast 42:1–2. https://doi.org/10.1016/j.breast.2018.08.096CrossRefPubMed

10.

Kawamoto T, Shikama N, Sasai K (2019) Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment. Radiother Oncol 131:240–241. https://doi.org/10.1016/j.radonc.2018.09.020CrossRefPubMed

Title: Ribociclib in Kombination mit endokriner Therapie verbessert Überleben von prä-/perimenopausalen Mammakarzinom-Patientinnen
Authors: Dr. med. David Krug
Alexander Fabian
Jürgen Dunst
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 3/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01574-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ribociclib in Kombination mit endokriner Therapie verbessert Überleben von prä-/perimenopausalen Mammakarzinom-Patientinnen

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 3/2020

Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results

Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years)

Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis

Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03)

Erste erfolgversprechende Ergebnisse der Kombination aus Strahlentherapie und Pembrolizumab beim metastasierten nichtkleinzelligen Lungenkarzinom

36. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik